Abstract
Perhaps there is no more important issue in the care of surgical patients than the appropriate use of minimally invasive surgery (MIS) for patients with cancer. Important advances in surgical technique have an impact on early perioperative morbidity, length of hospital stay, pain management, and quality of life issues, as clearly proved with MIS. However, for oncology patients, historically, the most important clinical questions have been answered in the context of prospective randomized trials. Important considerations for MIS and cancer have been addressed, such as what are the important immunologic consequences of MIS versus open surgery and what is the role of laparoscopy in the staging of gastrointestinal cancers? This review article discusses many of the key controversies in the minimally invasive treatment of cancer using the pro-con debate format.
MeSH terms
-
Animals
-
Combined Modality Therapy
-
Cytokines / metabolism
-
Esophageal Neoplasms / drug therapy
-
Esophageal Neoplasms / radiotherapy
-
Esophageal Neoplasms / surgery
-
Esophagectomy / methods
-
Humans
-
Immunity, Cellular
-
Immunosuppression Therapy
-
Immunotherapy
-
Inflammation
-
Intercellular Signaling Peptides and Proteins / metabolism
-
Laparoscopy / adverse effects
-
Laparoscopy / methods
-
Laparotomy / adverse effects
-
Laparotomy / methods
-
Length of Stay
-
Lymph Node Excision / methods
-
Minimally Invasive Surgical Procedures* / adverse effects
-
Neoplasms / immunology
-
Neoplasms / surgery*
-
Patient Selection
-
Pneumoperitoneum, Artificial / adverse effects
-
Postoperative Complications / etiology
-
Postoperative Complications / immunology
-
Randomized Controlled Trials as Topic
-
Stomach Neoplasms / surgery
-
Sus scrofa
Substances
-
Cytokines
-
Intercellular Signaling Peptides and Proteins